Breaking News Instant updates and real-time market news.

PFE

Pfizer

$36.64

0.06 (0.16%)

18:03
12/13/17
12/13
18:03
12/13/17
18:03

Pfizer announces FDA approves IXIFI, a biosimilar to Remicade

Pfizer announced that the United States FDA has approved IXIFI, a chimeric human-murine monoclonal antibody against tumor necrosis factor, as a biosimilar to Remicade for all eligible indications of the reference product. The FDA has approved IXIFI as a treatment for patients with rheumatoid arthritis, Crohn's disease, pediatric Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

  • 04

    Jan

PFE Pfizer
$36.64

0.06 (0.16%)

11/13/17
PIPR
11/13/17
NO CHANGE
Target $54
PIPR
Overweight
Pfizer still most compelling risk/reward in global pharma, says Piper Jaffray
Piper Jaffray analyst Richard Purkis says Pfizer remains the most compelling long-run risk/reward opportunity in his global pharma coverage universe. He believes the company's key growth assets, or Ibrance, Eliquis, Xtandi, Xeljanz and Bosulif, and pipeline are being underestimated by investors. Pfizer remains one of the analyst's top 2017 picks. Purkis reiterates an Overweight rating on the shares with a $54 price target.
11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
11/14/17
WELS
11/14/17
NO CHANGE
Target $12
WELS
Outperform
Pfizer ADHD drug supply shortage is positive for Neos, says Wells Fargo
Wells Fargo analyst David Maris says Pfizer (PFE) has sent a letter on physicians dated November 8th telling them of a supply shortage for its liquid and chewable methylphenidate ADHD products. Maris says Pfizer's product is a direct competitor of Neos' (NEOS) recently-launched Cotempla XR-ODT, adding Neos will benefit from having its primary competition in the alternative dose market facing a shortage. The analyst says Cotempla XR-ODT, launched in September, is off to a very strong start, keeping his Outperform rating with a $12 price target on Neos.
12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.

TODAY'S FREE FLY STORIES

CMCSA

Comcast

$34.98

(0.00%)

, CMCSK

Comcast

$0.00

(0.00%)

09:42
07/17/18
07/17
09:42
07/17/18
09:42
Periodicals
NBCU relaunches Craftsy as subscription-video service Bluprint, Variety reports »

NBCUniversal Cable…

CMCSA

Comcast

$34.98

(0.00%)

CMCSK

Comcast

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$124.70

(0.00%)

09:42
07/17/18
07/17
09:42
07/17/18
09:42
Hot Stocks
Johnson & Johnson says 'disappointed' in Spine & Knee medical sales results »

Says Spine still an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 08

    Aug

BA

Boeing

$356.01

(0.00%)

09:41
07/17/18
07/17
09:41
07/17/18
09:41
Hot Stocks
Boeing, Xiamen Airlines announce optimized maintenance program deal »

Boeing and Xiamen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

SNA

Snap-On

$163.93

(0.00%)

09:41
07/17/18
07/17
09:41
07/17/18
09:41
Recommendations
Snap-On analyst commentary  »

Snap-On checks point to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 16

    Aug

VEON

Veon

$3.05

(0.00%)

, HFC

HollyFrontier

$68.91

(0.00%)

09:40
07/17/18
07/17
09:40
07/17/18
09:40
Options
Unusually active option classes on open July 17th »

Unusual total active…

VEON

Veon

$3.05

(0.00%)

HFC

HollyFrontier

$68.91

(0.00%)

DUST

Direxion Daily Gold Miners Bear 3X ETF

$25.49

(0.00%)

UNH

UnitedHealth

$257.03

(0.00%)

JNJ

Johnson & Johnson

$124.70

(0.00%)

CZR

Caesars

$11.63

(0.00%)

GS

Goldman Sachs

$231.01

(0.00%)

MCD

McDonald's

$158.76

(0.00%)

ATVI

Activision Blizzard

$80.23

(0.00%)

GDX

Market Vector Gold Miners

$21.88

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 01

    Aug

  • 02

    Aug

  • 02

    Aug

  • 08

    Aug

NFLX

Netflix

$400.24

4.32 (1.09%)

09:38
07/17/18
07/17
09:38
07/17/18
09:38
Recommendations
Netflix analyst commentary  »

Netflix Q2 weakness is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEX

Wex

$194.01

-2 (-1.02%)

09:36
07/17/18
07/17
09:36
07/17/18
09:36
Initiation
Wex initiated  »

Wex initiated with a Peer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$231.01

4.71 (2.08%)

09:36
07/17/18
07/17
09:36
07/17/18
09:36
Periodicals
Lloyd Blankfein writes farewell memo to Goldman Sachs team, NY Times reports »

Goldman Sachs CEO LLoyd…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVRO

Nevro

$58.79

1.04 (1.80%)

09:35
07/17/18
07/17
09:35
07/17/18
09:35
Recommendations
Nevro analyst commentary  »

Nevro price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

FLT

FleetCor

$216.11

-4.06 (-1.84%)

09:35
07/17/18
07/17
09:35
07/17/18
09:35
Initiation
FleetCor initiated  »

FleetCor initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SQ

Square

$66.95

-0.06 (-0.09%)

09:35
07/17/18
07/17
09:35
07/17/18
09:35
Initiation
Square initiated  »

Square initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 15

    Aug

  • 16

    Aug

FIS

FIS

$107.72

-0.45 (-0.42%)

09:35
07/17/18
07/17
09:35
07/17/18
09:35
Initiation
FIS initiated  »

FIS initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

09:35
07/17/18
07/17
09:35
07/17/18
09:35
General news
Treasury Action: yields traded mixed-to-lower with stocks »

Treasury Action: yields…

EPAM

Epam Systems

$132.28

-1.3 (-0.97%)

09:34
07/17/18
07/17
09:34
07/17/18
09:34
Initiation
Epam Systems initiated  »

Epam Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 15

    Aug

  • 16

    Aug

PAYX

Paychex

$69.99

-0.57 (-0.81%)

09:34
07/17/18
07/17
09:34
07/17/18
09:34
Initiation
Paychex initiated  »

Paychex initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FISV

Fiserv

09:34
07/17/18
07/17
09:34
07/17/18
09:34
Initiation
Fiserv initiated  »

Fiserv initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

CLGX

CoreLogic

$53.31

0.04 (0.08%)

09:33
07/17/18
07/17
09:33
07/17/18
09:33
Initiation
CoreLogic initiated  »

CoreLogic initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

ADS

Alliance Data

$218.91

-24.58 (-10.09%)

09:33
07/17/18
07/17
09:33
07/17/18
09:33
Initiation
Alliance Data initiated  »

Alliance Data initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

WU

Western Union

$20.27

-0.09 (-0.44%)

09:33
07/17/18
07/17
09:33
07/17/18
09:33
Initiation
Western Union initiated  »

Western Union initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$137.13

-0.19 (-0.14%)

09:33
07/17/18
07/17
09:33
07/17/18
09:33
Initiation
ADP initiated  »

ADP initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

DXC

DXC Technology

$85.74

-0.41 (-0.48%)

09:32
07/17/18
07/17
09:32
07/17/18
09:32
Initiation
DXC Technology initiated  »

DXC Technology initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$167.63

-0.48 (-0.29%)

09:32
07/17/18
07/17
09:32
07/17/18
09:32
Initiation
Accenture initiated  »

Accenture initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$63.96

-0.74 (-1.14%)

09:32
07/17/18
07/17
09:32
07/17/18
09:32
Technical Analysis
Technical Earnings Preview: CSX may have double-topped before news »

On the 1-year, daily…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Aug

GPN

Global Payments

$117.00

-0.98 (-0.83%)

09:32
07/17/18
07/17
09:32
07/17/18
09:32
Initiation
Global Payments initiated  »

Global Payments initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

TSS

TSYS

09:31
07/17/18
07/17
09:31
07/17/18
09:31
Initiation
TSYS initiated  »

TSYS initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.